Feature | February 06, 2014| Dave Fornell

New EP Mapping Systems Enter the U.S. Market

Systems offer Improved Speed and Accuracy

New electrophysiology (EP) ablation mapping/navigation systems recently entered the U.S. market, each offering technology the vendors say will speed procedure time and improve procedural accuracy.
 
Boston Scientific’s Rhythmia Mapping System, a 3-D mapping and navigation system, gained U.S. Food and Drug Administration (FDA) 510(k) clearance in 2013. It is designed to intelligently automate map creation, increase speed and improve the density of mapping, capturing thousands versus hundreds of data points. The system also features vMap, a validation map, which is designed to enable EPs to rapidly confirm the endpoints of the ablation treatment. The intelligence built into the system also helps eliminate the need for manual annotation.
 
The Rhythmia mapping system works with Boston Scientific’s 64-electrode IntellaMap Orion high-resolution mapping catheter.
 
FIRM Rotor Mapping
Atrial fibrillation has proved to be an incredibly challenging arrhythmia to treat, and its complexity has defied interpretation and visualization by traditional EP mapping approaches. A relatively new technique has been developed using basket-mapping catheters to directly image myocardial bio-electrical rotors, an EP phenomenon shown in clinical studies to sustain atrial fibrillation.
 
Topera Inc. received 510(k) clearance in December for the latest generation of its 3D Mapping System. The new system has faster processing times, providing near-instantaneous intra-procedural mapping and re-mapping capabilities. The system incorporates a new color-imaging module to aid identification of rotors, an EP phenomenon previously shown to sustain atrial fibrillation. These functionalities enable EPs to more efficiently diagnose and ablate the cause of these complex arrhythmias.
 
Topera also gained approval for its FIRMap panoramic contactmapping basket catheter in the United States and Europe in late 2013. FIRMap is the first and only contact-mapping basket catheter cleared by the FDA for use in all cardiac chambers to assist in the diagnosis of complex arrhythmias. 

Related Content

The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Overlay Init